This is a routine procedural amendment to comply with SEC reporting requirements for significant subsidiaries. Traders should note that the inclusion of Armata's financials provides additional transparency into the financial health of Innoviva's primary investment, but does not signal any change in Innoviva's own operations, strategy, or financial condition. No trading action is warranted based on this filing alone.
Price Chart
Executive Summary
Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subsidiary, Armata Pharmaceuticals, Inc., which were not available at the time of the original filing. The amendment is routine and does not reflect changes to Innoviva's own financial statements or operations.
Key Facts
- The 10-K/A filing is an amendment to include Armata Pharmaceuticals' audited financial statements as required by Rule 3-09 of Regulation S-X.
- Armata is a clinical-stage biotechnology company focused on bacteriophage therapeutics, in which Innoviva holds a 68.8% ownership stake.
- The amendment was necessary because Armata's financial statements were not available when the original 10-K was filed on February 25, 2026.
- The explanatory note confirms that no other disclosures in the original filing have been updated or changed.
- The filing includes new certifications from Innoviva's CEO and CFO dated March 27, 2026, as required by SEC rules.
Financial Impact
No direct financial impact to Innoviva; the amendment is procedural and relates to subsidiary reporting requirements.
Risk Factors
- Armata's financial statements reveal substantial doubt about its ability to continue as a going concern, with only $8.7 million in cash as of December 31, 2025, which may raise concerns about the valuation of Innoviva's investment.
- Armata reported a significant net loss of $173.8 million in 2025, which could impact the carrying value of Innoviva's investment if further impairments are recognized.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-128939 |
| Document: inva-20251231.htm | 0001193125-26-128939 |
| Document: inva-ex32.htm | 0001193125-26-128939 |
| Document: inva-ex31_1.htm | 0001193125-26-128939 |
| Document: inva-ex31_2.htm | 0001193125-26-128939 |
| Document: inva-ex23_3.htm | 0001193125-26-128939 |
| Document: 0001193125-26-128939-index-headers.html | 0001193125-26-128939 |
| Document: 0001193125-26-128939-index.html | 0001193125-26-128939 |
| Document: 0001193125-26-128939.txt | 0001193125-26-128939 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 19w ago | 8-K | $21.73 $20.75 | ▼ −4.51% | ▼ −10.80% | $20.50 (−5.66%) |
May 6, 2026 21w ago | 8-K | $22.80 $20.77 | ▼ −8.90% | ▼ −12.74% | $20.50 (−10.09%) |
Mar 27, 2026 27w ago | 10-K/A | $22.91 $23.35 | ▲ +1.92% | ▼ −14.57% | $20.50 (−10.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access